Toxicophores: Groups and metabolic routes associated with increased safety risk

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 1, 2002, Pages 104-115

  Williams, Dominic P ^a   Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bioactivation; Metabolism; Reactive metabolite; Toxicophore

Indexed keywords

AMINOPHENAZONE; CARBAMAZEPINE; CLOZAPINE; HALOTHANE; OLANZAPINE; PARACETAMOL; REMOXIPRIDE; ROSIGLITAZONE; SULFAMETHOXAZOLE; TOXIC SUBSTANCE; TROGLITAZONE;

APLASTIC ANEMIA; BIOTRANSFORMATION; CELL FUNCTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HEPATITIS; HUMAN; LIVER FAILURE; MACROMOLECULE; REVIEW; RISK ASSESSMENT; SKIN ALLERGY;

ANIMALS; BIOTRANSFORMATION; EPOXY COMPOUNDS; HUMANS; METABOLISM; NITROGEN COMPOUNDS; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; QUINONES; TOXICOLOGY;

EID: 0036242414     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Basic concepts in drug metabolism: Part I
2. Idiosyncratic drug reactions: A mechanistic evaluation of risk factors
3. The role of active metabolites in drug toxicity
4. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective
5. New concepts in immunology relevant to idiosyncratic drug reactions: The 'danger hypothesis' and innate immunity system
6. Prediction of a new drug's potential to cause idiosyncratic reactions
7. Carcinogenesis by chemicals: An overview - G. H. A. Clowes memorial lecture
8. An investigation of the formation of cytotoxic, protein reactive and stable metabolites from carbamazepine in vitro
9. Adverse drug reactions and drug metabolism
10. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions
11. Immunologic mechanisms of cutaneous drug reactions
12. Basic concepts in drug metabolism: Part II
13. Peroxidase-dependent metabolism of benzene's phenolic metabolites and its potential role in benzene toxicity and carcinogenicity
14. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: Identification of target cells and a potential role for modulation of apoptosis in benzene toxicity
15. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis
16. Possible role of free radical formation in drug-induced agranulocytosis
17. Myeloperoxidase as a generator of drug free radicals
18. Change in occurrence of paracetamol overdose in UK after introduction of blister packs
19. Molecular mechanisms of the hepatotoxicity caused by acetaminophen
20. Paracetamol (acetaminophen)-induced toxicity: Molecular and biochemical mechanisms, analogues and protective approaches
21. Acetaminophen activation by human liver cytochromes P450IIE1 and P45OIA2
22. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4
23. Acetaminophen-induced hepatotoxicity
24. Mechanisms of acetaminophen toxicity: Immunochemical detection of drug-protein adducts
25. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury
26. 3-(Glutathion-S-yl)acetaminophen: A biliary metabolite of acetaminophen
27. Metabolism and excretion of a glutathione conjugate of acetaminophen in the isolated perfused rat kidney
28. Paracetamol, 3-monoalkyl- and 3,5-dialkyl derivatives. Comparison of their microsomal cytochrome P-450 dependent oxidation and toxicity in freshly isolated hepatocytes
29. Cytochrome P-450-mediated oxidation of substrates by electron-transfer; role of oxygen radicals and of 1- and 2-electron oxidation of paracetamol
30. Hydrogen atom abstraction of 3,5-disubstituted analogues of paracetamol by horseradish peroxidase and cytochrome P450
31. 15N-NMR relaxation studies
32. Hepatotoxic metabolic activation of paracetamol and its derivatives phenacetin and benorilate: Oxygenation or electron transfer?
33. The mechanism of prevention of paracetamol-induced hepatotoxicity by 3,5-dialkyl substitution. The roles of glutathione depletion and oxidative stress
34. Role of hepatic microsomal and purified cytochrome P-450 in one-electron reduction of two quinone imines and concomitant reduction of molecular oxygen
35. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen
36. Hepatocellular response to chemical stress in CD-1 mice: Induction of early genes and τ-glutamylcysteine synthetase
37. Effects of N-acetylcysteine and dithiothreitol on glutathione and protein thiol replenishment during acetaminophen-induced toxicity in isolated mouse hepatocytes
38. Reversal of acetaminophen toxicity in isolated hamster hepatocytes by dithiothreitol
39. The role of covalent binding to microsomal proteins in the hepatotoxicity of acetaminophen
40. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention
41. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
42. Histopathology of acetaminophen-induced liver changes: Role of interleukin 1α and tumor necrosis factor-α
43. Role of nitric oxide in acetaminophen-induced hepatotoxicity in the rat
44. Potential role of activated macrophages in acetaminophen hepatotoxicity. I. Isolation and characterization of activated macrophages from rat liver
45. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species
46. 2+ in the nucleus during acetaminophen-induced liver injury
47. 2+ in vivo early after hepatotoxic acetaminophen overdose in mice
48. A hepatotoxic dose of acetaminophen modulates expression of BCL-2, BCL-X(L), and BCL-X(S) during apoptotic and necrotic death of mouse liver cells in vivo
49. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors
50. A long-term study of remoxipride in chronic schizophrenic patients
51. Remoxipride in the treatment of psychoses
52. Adverse reaction reporting and new antipsychotics
53. Aplastic anaemia and remoxipride
54. Aplastic anaemia and remoxipride
55. Withdrawal of remoxipride
56. Disposition of remoxipride in different species. Species differences in metabolism
57. Overview of benzene-induced aplastic anaemia
58. Peroxidase activation of hydroquinone results in the formation of DNA adducts in HL-60 cells, mouse bone marrow macrophages and human bone marrow
59. The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line
60. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes
61. Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase
62. Effects of benzene metabolite treatment on granulocytic differentiation and DNA adduct formation in HL-60 cells
63. Oxidative DNA damage and apoptosis induced by benzene metabolites
64. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment
65. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies
66. Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19-human bone marrow progenitor cells: Potential relevance to remoxipride-induced aplastic anemia
67. Caspase-dependent and -independent mechanisms in apoptosis induced by hydroquinone and catechol metabolites of remoxipride in HL-60 cells
68. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells
69. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system
70. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate
71. Metabolism of carbamazepine
72. Bioactivation of carbamazepine in the rat in vivo - Evidence for the formation of reactive arene oxide(s)
73. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbemazepine by mouse liver microsomes
74. Mechanisms of halothane toxicity: Novel insights
75. The extent of metabolism of inhaled anesthetics in humans
76. Halothane biotransformation in man: A quantitative study
77. Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane
78. Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes
79. The association of halothane-induced lipid peroxidation with the anaerobic metabolism of halothane: An in vitro study in guinea pig liver microsomes
80. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis
81. Characterization of halothane oxidation by hepatic microsomes and purified cytochromes P-450 using a gas chromatographic mass spectrometric assay
82. Modification of liver microsomal lipids by halothane metabolites; a multi nuclear NMR spectroscopic study
83. Low-level binding of halothane metabolites to rat liver histones in vivo
84. The kidney as a novel target tissue for protein adduct formation associated with metabolism of halothane and the candidate chlorofluorocarbon replacement 2,2-dichloro-1,1,1-trifluoroethane
85. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury
86. Agranulocytosis caused by Chinese herbal medicines. Dangers of medications containing aminopyrine and phenylbutazone
87. Agranulocytosis due to the occurrence of leucocyte-agglutinins
88. Oxidation of aminopyrine by hypochlorite to a reactive dication: Possible implications for aminopyrine-induced agranulocytosis
89. The mechanism of myeloperoxidase-catalysed oxidation of aminopyrine
90. The formation of aminopyrine cation radical by the peroxidase activity of prostaglandin H synthase and subsequent reactions of the radical
91. Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants
92. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
93. A free radical mechanism of prostaglandin synthase-dependent aminopyrine demethylation
94. Neutropenia following amidopyrine
95. Halothane-induced liver injury in outbred guinea pigs: Role of trifluoroacetylated protein adducts in animal susceptibility
96. Guinea-pig model of halothane-associated hepatotoxicity in the absence of enzyme induction and hypoxia
97. A retrospective evaluation of adverse reactions to trimethoprim-sulphonamide combinations in dogs and cats
98. The risks and benefits of clozapine versus chlorpromazine
99. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
100. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
101. Biotransformation of clozapine in humans
102. Metabolism and bioactivation of clozapine by human liver in vitro
103. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man
104. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells
105. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland
106. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis
107. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine
108. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo
109. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes
110. The cytotoxicity of clozapine metabolites: Implications for predicting clozapine-induced agranulocytosis
111. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis
112. Mechanism of action of clozapine-induced agranulocytosis: Current status of research and implications for drug development
113. Hepatotoxicity of clozapine
114. Structural features associated with reactive metabolite formation in clozapine analogues
115. A short survey on untoward effects of fluperlapine
116. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study
117. Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis
118. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis
119. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes
120. General and epidemiological aspects of allergic drug reactions
121. Pathogenesis and management of HIV-associated drug hypersensitivity
122. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction
123. Drug-specific cytotoxic T-lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis (TEN)
124. Sulfamethoxazole is metabolized to the hydroxylamine in humans
125. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity
126. Cellular disposition of sulphamethoxazole and its metabolites: Implications for hypersensitivity
127. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions
128. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat
129. Antigenicity and immunogenicity of sulphamethoxazole: Demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo
130. Induction of delayed-type hypersensitivity to sulfamethoxazole in mice: Role of metabolites
131. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine
132. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human αβ T-cell clones
133. Degeneracy and additional alloreactivity of drug-specific human αβ (+) T-cell clones
134. New uses for old drugs in HIV infection: The role of hydroxyurea, cyclosporin and thalidomide
135. Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family
136. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat
137. Idiosyncratic reactions to drugs: Can medicine response profiles provide a dynamic drug surveillance system?
138. cDNA microarray and SNP analysis
139. Genome research and anticancer chemotherapy
140. High-throughput genomic and proteomic analysis using microarray technology
141. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs